Navigation Links
Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment

LOS ANGELES (PRWEB) August 05, 2013

Baron and Budd is proud to announce the Food and Drug Administration’s approval of a new drug to be used for the treatment of the rare cancer, mesothelioma, that occurs because of exposure to asbestos. This new drug is called VS-6036, or defactinib, and is a cancer-stem-cell inhibitor that is manufactured by Verastem Inc. (VSTM). (

VS-6036 is being developed thanks to the Food and Drug Administration’s orphan drug designation that assists the development of drugs treating rare conditions affecting 200,000 patients or less within the U.S. With this designation, VS-6036 has been given assistance from the Food and Drug Administration in clinical trial development, pardon from the standard Food and Drug Administration user fees and a seven-year market exclusivity period after approval. (

Up to 400 patients are planned to enroll in clinical trial sites in 11 countries for the VS-6036 clinical study for patients suffering from pleural mesothelioma.

“We are encouraged by the work of the FDA and Verastem Inc. to better the lives of those suffering from mesothelioma," said Russell Budd of Baron and Budd. “While the FDA and Verastem Inc. prepare the VS-6036 clinical trial, we will continue to work to make sure that one day the need for mesothelioma treatment is irrelevant. We believe that a global ban on asbestos is imperative."

To find out more about asbestos exposure, mesothelioma and the road toward banning asbestos use within the United States, visit

Baron and Budd is an active participant in asbestos advocacy and mesothelioma education on a national scale. The law firm supports the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the countries’ top cancer treatment centers. With financial support from Baron and Budd, the NCCN has been able to produce and distribute a treatment resource detailing the Clinical Guidelines for Mesothelioma, titled the Patient Guidelines for Mesothelioma. Baron and Budd is also a repeat platinum sponsor of an international non-profit organization committed to banning asbestos and assisting patients suffering from mesothelioma, the Asbestos Disease Awareness Organization (ADAO). Baron and Budd was also an inaugural donor to the International Mesothelioma Program (IMP) at Brigham and Women’s Hospital in Boston.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
2. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
3. Study Supports Value of Sigmoidoscopy, an Alternative to Colonoscopy
4. Study supports urate protection against Parkinsons disease, hints at novel mechanism
5. Dietary fiber alters gut bacteria, supports gastrointestinal health
6. Narconon Louisiana Supports United Nations International Day Against Drug Abuse and Illicit Trafficking
7. NIDA supports development of combined anti-heroin and HIV vaccine
8. Little evidence supports autism treatment options in adolescents
9. $1.8 million grant supports investigation of psoriasis link to cardiovascular disease
10. John Templeton Foundation grant supports Princeton neuroscientists to study cognitive control
11. Human umbilical cord blood cell co-culture supports embryonic stem cell expansion
Post Your Comments:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: